Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3311 - Patients (pts) with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP)

Date

10 Sep 2017

Session

Poster display session

Presenters

Avivit Peer

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

A. Peer1, K. Savion2, K. Rouvinov3, R. Leibowitz-Amit4, R. Berger4, A. Sella5, V. Neiman6, E. Rosenbaum6, W. Mermershtain3, A. Neumann1, M. Kolin1, R. Perets1, D. Keizman7

Author affiliations

  • 1 Oncology, Rambam Health Care Center, 31096 - Haifa/IL
  • 2 School Of Medicine, Technion, Haifa/IL
  • 3 Oncology, Soroka University Medical Center, 84101 - Beer Sheva/IL
  • 4 Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 5 Oncology, Asaf Harofeh Medical Center, 70300 - Zerifin/IL
  • 6 Oncology, Rabin Medical Center, Petah Tikva/IL
  • 7 Oncology, Meir Medical Center, Kfar Saba/IL
More

Resources

Abstract 3311

Background

Immunotherapy with the andi-PD1 Nivo is a standard ATL for clear cell mRCC. Data on its activity in the rare variant of mnccRCC is limited (case reports). We aimed to report the activity of Nivo in mnccRCC pts treated per a national EAP.

Methods

Records from consecutive mnccRCC pts treated with Nivo ATL per a national EAP in 6 centers were retrospectively reviewed. We report the clinical benefit, progression free survival (PFS), overall survival (OS), and toxicity.

Results

Between 7/2015 – 12/2016, 16 mnccRCC pts (median age 64, male 68%; papillary type 38%, n = 6; chromophobe 44%, n = 7; undifferentiated 12%, n = 2; pure sarcomatoid 6%, n = 1). 62% (n = 10) were treated with second line Nivo, and 38% (n = 6) as third and fourth line. Heng risk was good/intermediated/poor in 6% (n = 1)/75% (n = 12)/19% (n = 3). Clinical benefit (stable disease+ partial response) was 37% (4 partial response and 2 stable disease). Median PFS was 3.5 months (mos). After a median follow up time of 8 mos, 100% of the pts with a clinical benefit are still with a benefit and on treatment (range 5-18m). Most pts (69%, n = 11) are alive, with median OS not reached. Toxicity was mild grade 1-2 in the majority of pts (56%, n = 9).

Conclusions

Nivo as ATL may be active in mnccRCC pts, and associated with durable responses and predictable mild toxicity. Future and larger studies are needed to assess the activity of immunotherapy in this uncommon type of mRCC.

Clinical trial identification

Legal entity responsible for the study

the author

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.